抄録
The use of activated charcoal for direct hemoperfusion (DHP) was attempted by Yatzidis in 1964 and by Chang in 1970. Since then, this method has come into wide use as a symptomatic therapy for drug intoxication, renal failure and hepatic failure.
In DHP therapy, however, the release of microparticles of charcoal causing thrombogenesis is the main problem.
Charcoal derived from thermosetting resin (CTSR) is more rigid than many kinds of activated charcoal used in the medical field. Furthermore, in vitro and in vivo experiments, it is suggested that this charcoal has superior adsorbability for many toxins and it will be available for DHP.
